PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

Shares of NASDAQ:TXG opened at $10.34 on Friday. The stock has a market capitalization of $1.26 billion, a P/E ratio of -6.80 and a beta of 1.93. 10x Genomics has a 1-year low of $9.27 and a 1 ...

PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...

10x Genomics (NASDAQ:TXG – Get Free Report) had its price target reduced by investment analysts at Citigroup from $20.00 to $15.00 in a note issued to investors on Tuesday,Benzinga reports.

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly filed against Vizgen Inc. in 2022, alleging that Vizgen unlawfully used ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East ...

However, only $17.5 billion, less than half, represents genuine long-only buying, reported 10x Research head of research Markus Thielen. The majority, or around 56%, “is likely tied to arbitrage ...

Popcorn is one of my all-time favorite snacks, especially now that I have to eat gluten-free. It's a quick way to fill me up without having to worry about what's in it. Whether it's buttery movie ...